The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Corbus Pharmaceuticals Holding stock forecast from 4 analysts, the average analyst target price for Corbus Pharmaceuticals Holding is USD 77.83 over the next 12 months. Corbus Pharmaceuticals Holding’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Corbus Pharmaceuticals Holding is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Corbus Pharmaceuticals Holding’s stock price was USD 50.04. Corbus Pharmaceuticals Holding’s stock price has changed by -18.21% over the past week, -5.48% over the past month and +608.78% over the last year.
No recent analyst target price found for Corbus Pharmaceuticals Holding
No recent average analyst rating found for Corbus Pharmaceuticals Holding
Company Overview Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Read Less
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E...Read More
Frequently Asked Questions About Corbus Pharmaceuticals Holding (CRBP) Stock
Based on ratings from 4 analysts Corbus Pharmaceuticals Holding's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 12 buy, sell and hold ratings.
Unfortunately we do not have enough data on CRBP's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for CRBP is USD 77.83 over the next 12 months. The maximum analyst target price is USD 88 while the minimum anlayst target price is USD 58.
Unfortunately we do not have enough data on CRBP's stock to indicate if its overvalued.
The last closing price of CRBP's stock was USD 50.04.
The most recent market capitalization for CRBP is USD 0.67B.
Based on targets from 4 analysts, the average taret price for CRBP is projected at USD 77.83 over the next 12 months.
This means that CRBP's stock price may go up by +55.54% over the next 12 months.
We can't find any ETFs which contains Corbus Pharmaceuticals Holding's stock.
As per our most recent records Corbus Pharmaceuticals Holding has 19 Employees.
Corbus Pharmaceuticals Holding's registered address is 500 River Ridge Drive, Norwood, MA, United States, 02062.
You can get more information about it from Corbus Pharmaceuticals Holding's website at https://www.corbuspharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Corbus Pharmaceuticals Holding (CRBP) Stock
Based on ratings from 4 analysts Corbus Pharmaceuticals Holding's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 12 buy, sell and hold ratings.
Unfortunately we do not have enough data on CRBP's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for CRBP is USD 77.83 over the next 12 months. The maximum analyst target price is USD 88 while the minimum anlayst target price is USD 58.
Unfortunately we do not have enough data on CRBP's stock to indicate if its overvalued.
The last closing price of CRBP's stock was USD 50.04.
The most recent market capitalization for CRBP is USD 0.67B.
Based on targets from 4 analysts, the average taret price for CRBP is projected at USD 77.83 over the next 12 months.
This means that CRBP's stock price may go up by +55.54% over the next 12 months.
We can't find any ETFs which contains Corbus Pharmaceuticals Holding's stock.
As per our most recent records Corbus Pharmaceuticals Holding has 19 Employees.
Corbus Pharmaceuticals Holding's registered address is 500 River Ridge Drive, Norwood, MA, United States, 02062.
You can get more information about it from Corbus Pharmaceuticals Holding's website at https://www.corbuspharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CRBP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
